Karyopharm to Present Selinexor Data at 2023 International Myeloma Society Meeting in Athens, SIENDO Study Findings to Feature in ESGO Congress 2023's Best Oral Session in Istanbul
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced that new selinexor data will be presented at the 2023 International Myeloma Society Annual Meeting in Athens, Greece. Additionally, findings from the SIENDO Study on patients with advanced or recurrent TP53 wild-type endometrial cancer will be featured in the 2023 European Society of Gynaecological Oncology Congress in Istanbul, Turkey.
September 26, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karyopharm's announcement of presenting new data on selinexor and SIENDO Study findings at major conferences could potentially boost investor confidence in the company's research and development efforts.
Presenting new data at major conferences often indicates significant progress in a company's research and development efforts. This could potentially attract more investors, leading to a positive impact on the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100